



**COMBINED GENERAL MEETING
JUNE 21, 2023**

Company's Supervisory Board

**Including the information required pursuant to
Article R. 225-83, 5° of the French Commercial Code,
in connection with proposals for the appointment or
reappointment of Supervisory Board members**



1. SUPERVISORY BOARD

The Company's Supervisory Board is currently composed of the following members:

- Mr. Frédéric GRIMAUD, Chair of the Board;
- Mr. James SULAT, Vice-Chair of the Board;
- Ms. Anne-Marie GRAFFIN;
- Ms. Sharon TETLOW; and
- Ms. Johanna PATTENIER;
- Mr. James CONNOLLY; and
- BpiFrance Participations represented by Ms. Maïlys FERRÈRE.

Please note: it is proposed to the shareholders of this Combined General Meeting to reappoint the following Supervisory Board members:

- Ms. Johanna Pattenier (Resolution 5)
- Ms. Sharon Tetlow (Resolution 6)

It is also proposed to the shareholders of this Combined General Meeting to appoint a new member at the Company's Supervisory Board:

- Ms. Kathrin Jansen (Resolution 7)



VALNEVA SE - MANAGEMENT BOARD AND SUPERVISORY BOARD



Ms. Johanna PATTENIER MEMBER OF VALNEVA SE'S SUPERVISORY BOARD (63 YEARS OLD)

Appointment to Valneva SE's Supervisory Board by the Ordinary General Meeting on June 17, 2020

End of term of office at the 2023 General Meeting called to approve the annual financial statements for the fiscal year ended December 31, 2022

INDEPENDENT	AUDIT AND GOVERNANCE COMMITTEE	NOMINATION AND COMPENSATION COMMITTEE	EXPERIENCE AND EXPERTISE
Yes	Member since May 4, 2022 until June 23, 2022	Member since June 17, 2020	Seasoned executive with more than two decades of market access, medical and commercial experience in the pharmaceutical industry

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE ⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

–

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

–

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

–

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

–

⁽¹⁾ Current listed companies are indicated by (*).



VALNEVA SE - MANAGEMENT BOARD AND SUPERVISORY BOARD



Ms. Sharon TETLOW MEMBER OF VALNEVA SE'S SUPERVISORY BOARD (62 YEARS OLD)

Appointment to Valneva SE's Supervisory Board by the Ordinary General Meeting on June 17, 2020

End of term of current office at the 2023 General Meeting called to approve the annual financial statements for the fiscal year ended December 31, 2022

INDEPENDENT	AUDIT AND GOVERNANCE COMMITTEE	NOMINATION AND COMPENSATION COMMITTEE	EXPERIENCE AND EXPERTISE
Yes	Chair since March 23, 2021 (and member since June 17, 2020)	—	Seasoned financial executive with more than three decades specializing in the life sciences industry

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE ⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Structure Therapeutics Inc.

(formerly ShouTi Inc.)

- Member of the Board of Directors (Administrateur), since March 2022
- Chair of the Audit Committee (Présidente du Comité d'audit), since March 2022

Altamont Pharma Acquisition Corp.

- Member of the Board of Directors, since February 2021

Dice Molecules, Inc.

- Member of the Nominating and Governance committee since February 2021
- Member of the Board of Directors, since November 2020
- Chair of the Audit Committee, since November 2020

Catalyst Biosciences, Inc. ^(*)

- Member of the Board of Directors, since January 2020
- Chair of the Audit Committee, since June 2020

OTHER POSITIONS

Katherine Michiels School, Project Open Mind

- Board member, since February 2016

(1) Current listed companies are indicated by (*).

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Altamont Pharma Acquisition Corp.

- Member of the Board of Directors, from February 2021 to January 2022

Armetheon, Inc.

- Member of the Board of directors, from November 2016 to September 2017
- Member of the Audit Committee, from November 2016 to September 2017
- Member of the Transaction Committee



CAPITAL HELD BY THE SUPERVISORY BOARD MEMBERS WHOSE REAPPOINTMENT IS PROPOSED TO THE SHAREHOLDERS

Information at December 31, 2022

Currently, Ms. Pattenier and Ms. Tetlow do not hold any shares of the Company Valneva SE.



MS. KATHRIN U JANSEN

PROPOSAL FOR APPOINTMENT

AS MEMBER OF THE SUPERVISORY BOARD OF VALNEVA SE

Dr Kathrin U Jansen, Ph.D., age 65, is a German national with over 30 years of vaccine R&D experience focused on the development of vaccines addressing large unmet medical needs. From 2015 to 2022 she served as Senior Vice President and Head of Vaccine Research and Development (VRD) at Pfizer Inc, and a member of Pfizer's Worldwide Research, Development and Medical leadership team and led a fully integrated, global vaccines research and development organization, with responsibilities ranging from discovery to clinical development, registration, and post-marketing commitments of all of Pfizer's vaccines, including partnered ones. Most notably she led the development of several highly successful and licensed vaccines such as Pfizer/BioNtech's SARS-CoV-2 (COMIRNATY®), the first-ever licensed mRNA vaccine, Pfizer's Streptococcus pneumoniae (Prevnar 20®), Respiratory syncytial virus (Abrysvo®), and Meningococcal B Group B (Trumenba®) vaccines. From 2006 to 2015, Dr. Jansen served as Senior Vice President at Wyeth Pharmaceuticals and then Pfizer and was responsible for vaccine discovery, early development, and clinical testing operations. Prior to Wyeth, Dr. Jansen spent 12 years at Merck Research Laboratories supporting several vaccine efforts and leading the R&D activities of Gardasil®, the world's first cervical cancer vaccine. Dr. Jansen received her PhD in microbiology, biochemistry & genetics from Phillips Universitaet, Marburg, Germany, in 1984 followed by postdoctoral training at Cornell University.

Dr. Jansen was appointed an Adjunct Professor at the University of Pennsylvania School of Medicine in 2010 and has authored and co-authored over 200 publications. She is a member of the National Academy of Medicine, National Academy of Engineering, a Fellow of the Royal Society of Medicine and recipient of the Albert E Sabin Gold Medal.

Currently, Ms. Jansen does not hold any shares of the Company Valneva SE.